TY - JOUR
T1 - The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events
T2 - A case/non-case study using VigiBase
AU - Aguiar, João Pedro
AU - Alves da Costa, Filipa
AU - Egberts, Toine
AU - Leufkens, Hubert
AU - Souverein, Patrick
N1 - Funding Information:
The authors thank the Uppsala Monitoring Centre for making their pharmacovigilance data available for this study and the participating national pharmacovigilance centres for their contribution to VigiBase. We also would like to acknowledge the Ph.D. grant ( SFRH/BD/132785/2017 ) provided to JPA by the Fundação para a Ciência e a Tecnologia, I.P. ( FCT ), Lisboa, Portugal.
Funding Information:
Authors have no conflict of interest to disclose of financial, personal or of any other nature that may bias the work. The authors thank the Uppsala Monitoring Centre for making their pharmacovigilance data available for this study and the participating national pharmacovigilance centres for their contribution to VigiBase. We also would like to acknowledge the Ph.D. grant (SFRH/BD/132785/2017) provided to JPA by the Funda??o para a Ci?ncia e a Tecnologia, I.P. (FCT), Lisboa, Portugal. The information in this article does not represent the opinion of the World Health Organization, the Uppsala Monitoring Centre, nor the national pharmacovigilance centres.
Publisher Copyright:
© 2020
PY - 2020/6
Y1 - 2020/6
N2 - Antipsychotics (APs) have been associated with major adverse cardio- and cerebrovascular events (MACCE), but the underlying mechanisms are unclear. Our aim was to elucidate the association between APs, stratified for receptor affinity and metabolic side effects (MSE), in the reporting of MACCE. A case/non-case study was conducted using data from the WHO global Individual Case Safety Report (ICSR) database, VigiBase, among all reports associated with an AP. Cases were ICSRs of MACCE, while non-cases were all other adverse drug reactions (ADRs). APs were classified by AP group, the degree of receptor affinity for adrenergic, dopaminergic, muscarinic, histaminic, and serotoninergic receptors and by MSE profile. The strength of the association was estimated with logistic regression and expressed as crude and adjusted reporting odds ratios (RORadj.) with corresponding 95% confidence intervals (95%CIs). We identified 4987 reports of MACCE and 328,907 reports of other ADRs. Atypical APs (RORadj. 2.46; 95%CI 2.20–2.74) were significantly associated with the reporting of MACCE compared to typical ones. APs with high affinity for Adrenergic alfa-1 (RORadj. 2.98; 95%CI 1.93–4.59), Histaminic H1 (RORadj. 2.31; 95%CI 1.98–2.68), Muscarinic M1 (RORadj. 1.87; 95%CI 1.74–2.01), and Serotoninergic 5-HT2A (RORadj. 3.19; 95%CI 2.07–4.92) were associated with a higher risk of reporting of MACCE compared to low affinity. APs with higher-risk of MSE were associated with higher risk of reporting of MACCE (RORadj. 1.88; 95%CI 1.73–2.05) compared to the lower-risk. APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A receptors and with high-risk of MSE may explain the occurrence of those events.
AB - Antipsychotics (APs) have been associated with major adverse cardio- and cerebrovascular events (MACCE), but the underlying mechanisms are unclear. Our aim was to elucidate the association between APs, stratified for receptor affinity and metabolic side effects (MSE), in the reporting of MACCE. A case/non-case study was conducted using data from the WHO global Individual Case Safety Report (ICSR) database, VigiBase, among all reports associated with an AP. Cases were ICSRs of MACCE, while non-cases were all other adverse drug reactions (ADRs). APs were classified by AP group, the degree of receptor affinity for adrenergic, dopaminergic, muscarinic, histaminic, and serotoninergic receptors and by MSE profile. The strength of the association was estimated with logistic regression and expressed as crude and adjusted reporting odds ratios (RORadj.) with corresponding 95% confidence intervals (95%CIs). We identified 4987 reports of MACCE and 328,907 reports of other ADRs. Atypical APs (RORadj. 2.46; 95%CI 2.20–2.74) were significantly associated with the reporting of MACCE compared to typical ones. APs with high affinity for Adrenergic alfa-1 (RORadj. 2.98; 95%CI 1.93–4.59), Histaminic H1 (RORadj. 2.31; 95%CI 1.98–2.68), Muscarinic M1 (RORadj. 1.87; 95%CI 1.74–2.01), and Serotoninergic 5-HT2A (RORadj. 3.19; 95%CI 2.07–4.92) were associated with a higher risk of reporting of MACCE compared to low affinity. APs with higher-risk of MSE were associated with higher risk of reporting of MACCE (RORadj. 1.88; 95%CI 1.73–2.05) compared to the lower-risk. APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A receptors and with high-risk of MSE may explain the occurrence of those events.
KW - Antipsychotics
KW - Major adverse Cardio- and cerebrovascular events
KW - Pharmacoepidemiology
KW - Pharmacovigilance
UR - http://www.scopus.com/inward/record.url?scp=85084484912&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2020.03.022
DO - 10.1016/j.euroneuro.2020.03.022
M3 - Article
C2 - 32409260
AN - SCOPUS:85084484912
SN - 0924-977X
VL - 35
SP - 30
EP - 38
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
ER -